Modified cold sore virus injected into tumors in early cancer trial
NCT ID NCT04336241
Summary
This is an early-stage safety study testing a new treatment called RP2, which is a genetically modified cold sore virus designed to kill cancer cells and boost the immune system. It is being given alone and in combination with an existing immunotherapy drug (nivolumab) to adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the treatment shows any early signs of shrinking tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Churchill Hospital
Oxford, OX3 9DU, United Kingdom
-
Hospital Clinico de Valencia
Valencia, 46010, Spain
-
Hospital Universitario HM Sanchinarro
Madrid, 10 28050, Spain
-
Hospital Universitario d'Hebron
Barcelona, 119 08035, Spain
-
The Clatterbridge Cancer Centre NHS Foundation Trust
Bebington, Merseyside, CH63 4JY, United Kingdom
-
The Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
Conditions
Explore the condition pages connected to this study.